Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from October 29, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on January 27, 2026 — +19.9% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$51.50 – $53.00Entry zone — fair-value band

$52.45Published — price the day we called it

$62.42Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$62.89Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 85 days.

At window close

+19.9%

realized, from the publication price to the last close inside the window

Peak gain

+22.3%

peak, from the publication price — not a realized return

S&P 500, same window

+1.5%

SPY over the identical days, dividend-adjusted

Window close

$62.89

last close inside the window, ended January 27, 2026

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Days to target

The thesis — published October 29, 2025

Predicted growth

+19%

over the measurement window

Target price

$62.42

the price the thesis aimed for

Entry zone

$51.50 – $53.00

the fair-value band we waited for

Price at publication

$52.45

published October 29, 2025

Confidence

66%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk's share price has cooled off after a sharp drop, just as a big FDA decision on the pill version of Wegovy approaches. Job cuts tied to a reorg may cause headlines, but the core business is still strong. Over the next 0-3 months, a positive ruling could lift mood and price. Buying near $52 aims for a fair entry while staying mindful that any delay in the decision could push the timeline out.

Primary drivers

Key FDA call on oral Wegovy that could expand the obesity treatment market
Price pulled back hard, so even modest good news may spark a stronger rebound
Healthy profits and cash flow support ongoing research, launches, and scaling
Restructuring headlines may distract investors and add short-term ups and downs

How it played out

NVO: target reached in 85 days

Lyra published NVO at $52.45 on 2025-10-29, with 19% expected growth over a short-term window. The thesis pointed to a key FDA call on oral Wegovy, a hard price pullback, healthy profits and cash flow, and restructuring headlines that could add short-term ups and downs.

Inside the window, the stock reached the $62.42 target in 85 days. It peaked at $64.16 on 2026-01-23, a 22.3% gain. It ended the window at $62.89 on 2026-01-27. The thesis played out.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals